antibody-drug conjugates

News

MSD sinks $4bn upfront into ADC pact with Daiichi Sankyo

Daiichi Sankyo’s antibody-drug conjugate (ADC) franchise has generated another massive licensing deal, this time from MSD, which is paying $4 billion upfront for rights to

News

Lilly makes another ADC play, buying Mablink

Eli Lilly has agreed a deal to acquire French antibody-drug conjugate (ADC) specialist Mablink, continuing a series of transactions that build its position in what has bec

News

Seagen partners Nurix on 'degrader-antibody conjugates'

Seagen hasn't let a pending acquisition by Pfizer interrupt its business development activities, adding to its pipeline with a wide-ranging partnership with Nurix Therapeu

News

FTC asks for more info on Pfizer’s $43bn Seagen takeover

The US Federal Trade Commission (FTC) has asked for more information on Pfizer’s $43 billion agreement to acquire Seagen before it will deliver a decision on whether the d

News

Lonza builds its ADC capacity with Synaffix takeover

Lonza has boosted its ability to cater for customers in the fast-emerging antibody-drug conjugate category with a deal to buy Dutch company Synaffix and its platform techn

News

BMS goes down the Tubulis route for cancer ADCs

Bristol-Myers Squibb has formed another alliance focusing on antibody-drug conjugates (ADCs) for solid tumours, paying German biotech Tubulis $22.75 million upfront to get

MSD sinks $4bn upfront into ADC pact with Daiichi Sankyo

Lilly makes another ADC play, buying Mablink

Seagen partners Nurix on 'degrader-antibody conjugates'

FTC asks for more info on Pfizer’s $43bn Seagen takeover

Lonza builds its ADC capacity with Synaffix takeover

BMS goes down the Tubulis route for cancer ADCs

CDMOs: Their crucial role and how to select one, with Sigma ...

How to meet your physicians where they are online

antibody-drug conjugates

Editor's Picks